巴多昔芬联合结合雌激素治疗子宫内膜异位症
本文报道一例III期子宫内膜异位症患者,因痛经和周期性盆腔痛转诊,接受巴多昔芬20 mg联合结合雌激素0.45 mg每日治疗超过6个月,盆腔痛缓解,激素、子宫及卵巢参数无异常。作者认为该方案可能成为传统子宫内膜异位症治疗的有效替代选择。
要点
- 巴多昔芬20 mg联合结合雌激素0.45 mg每日治疗超过6个月,患者盆腔痛缓解。
- 治疗期间激素、子宫及卵巢参数无异常影响。
- 作者认为该方案可能为子宫内膜异位症的有效替代治疗选择。
核心结论
- 巴多昔芬联合结合雌激素可能成为传统子宫内膜异位症治疗的有效替代选择。
研究设计与样本
- 病例报告:一例III期子宫内膜异位症患者,因痛经和周期性盆腔痛转诊接受治疗。
主要发现
- 患者接受巴多昔芬20 mg联合结合雌激素0.45 mg每日治疗超过6个月后盆腔痛缓解。
- 治疗期间激素、子宫及卵巢参数无异常影响。
临床怎么用
- 作者认为巴多昔芬联合结合雌激素可能成为传统子宫内膜异位症治疗的有效替代选择。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Endometriosis is a gynecologic disorder affecting 6-10% of reproductive-aged women. First-line therapies are progestin-based regimens; however, failure rates are high, often requiring alternative hormonal agents, each with unfavorable side effects. Bazedoxifene with conjugated estrogens is approved for treatment of menopausal symptoms, and use in animal studies has demonstrated regression of endometriotic lesions. As such, it represents a potential treatment option for endometriosis. CASE: A patient with stage III endometriosis referred for management of dysmenorrhea and cyclic pelvic pain was treated with 20 mg bazedoxifene and 0.45 mg conjugated estrogens daily for more than 6 months. She noted resolution of pelvic pain. There were no abnormal effects on hormonal, uterine, or ovarian parameters. CONCLUSION: Bazedoxifene with conjugated estrogens may be an effective alternative to traditional endometriosis treatment options.
引用
- Flores VA, Stachenfeld NS, Taylor HS, et al. Bazedoxifene-Conjugated Estrogens for Treating Endometriosis. Obstet Gynecol. 2018. PMID: 29995747. doi:10.1097/AOG.0000000000002739
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。